Sanofi's next chap­ter in Pompe: $150M for Maze pact as the biotech gears up in CKD

With near­ly $400 mil­lion to its name since Third Rock launched the biotech in 2019, Maze Ther­a­peu­tics has lined up a deal that sees Sanofi snag its Pompe dis­ease pro­gram af­ter tout­ing Phase I da­ta in March and last De­cem­ber.

Sanofi will pay $150 mil­lion in up­front cash and fu­ture eq­ui­ty in the pri­vate biotech and an­oth­er $600 mil­lion could come Maze’s way via biobucks for its oral can­di­date MZE001, back-up pro­grams and IP around its GYS1 pro­gram, the com­pa­nies said Mon­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER